What was filed
Jagsonpal Pharmaceuticals submitted the annual disclosure required under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, covering the financial year ended 31 March 2026. Despite the "substantial acquisition" heading on the regulation, this is not an acquisition — Regulation 31(4) requires promoters to make a yearly declaration about whether they have encumbered (pledged, mortgaged or otherwise charged) their shares.
The filing bundles declarations from the company's promoter groups, including the Rajpal Singh Kochhar / Aresko group and the Mauritius-based Infinity Holdings group. Each declared that no encumbrance had been created over their shares, directly or indirectly, during or as on the year ended 31 March 2026.
Why it matters to a holder
Promoter share pledging is a risk signal watched by shareholders, because pledged promoter stock can be sold by lenders if margin calls are triggered, adding pressure on the price. This is a routine, calendar-driven compliance filing rather than a corporate event, and it confirms the absence of such encumbrances for the reported year. The disclosure also lists the full promoter and promoter-group structure — 38 named entities in Annexure A — for the record.